Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02897765 · ClinicalTrials.gov registry record · Phase 1
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
A Phase 1 study, sponsored by BioNTech US.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02897765: Completed Phase 1 study, sponsored by BioNTech US.
NCT02897765 is a Phase 1 study that has completed, run by BioNTech US. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02897765, a Phase 1 study, has completed, sponsored by BioNTech US.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a substantial improvement over other available therapies such as nivolumab alone. All eligible patients will receive NEO-PV-01 + adjuvant and nivolumab while on this trial.
Primary Outcome
Rate of adverse events including SAEs and AEs leading to treatment discontinuation
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL NEO-PV-01
- OTHER Adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-05 |
| Phase | Phase 1 |
What the finished NCT02897765 record still lists
NCT02897765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02897765 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02897765 about?
NCT02897765 is a clinical study titled "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer". The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a substantial improvement over other av...
What is the current status of trial NCT02897765?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2016-10. Estimated completion is 2020-05.
What interventions are being tested in trial NCT02897765?
The interventions under investigation include: Nivolumab (BIOLOGICAL), NEO-PV-01 (BIOLOGICAL), Adjuvant (OTHER).
Who is sponsoring clinical trial NCT02897765?
This trial is sponsored by BioNTech US, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02897765's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia